Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy
Khalid Saad Alharbi, Mohammad Arshad Javed Shaikh, Obaid Afzal, et al.
Chemico-Biological Interactions (2022) Vol. 366, pp. 110108-110108
Closed Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Unveiling the connection: Long-chain non-coding RNAs and critical signaling pathways in breast cancer
Riya Thapa, Obaid Afzal, Gaurav Gupta, et al.
Pathology - Research and Practice (2023) Vol. 249, pp. 154736-154736
Closed Access | Times Cited: 78
Sodium alginate-based drug delivery for diabetes management: A review
Mohammad Arshad Javed Shaikh, Gaurav Gupta, Obaid Afzal, et al.
International Journal of Biological Macromolecules (2023) Vol. 236, pp. 123986-123986
Closed Access | Times Cited: 32
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
GAS5 lncRNA: A biomarker and therapeutic target in breast cancer
Lakshmi Thangavelu, Ehssan Moglad, Gaurav Gupta, et al.
Pathology - Research and Practice (2024) Vol. 260, pp. 155424-155424
Closed Access | Times Cited: 10
Advances in erlotinib delivery systems: Addressing challenges and exploring opportunities in EGFR-targeted cancer therapies
Mehrab Pourmadadi, Vahideh Mohammadzadeh, Zahra Mohammadi, et al.
Inorganic Chemistry Communications (2024) Vol. 161, pp. 112114-112114
Closed Access | Times Cited: 9
The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer
Mohammed H. Abu-Alghayth, Farhan R. Khan, Tareg M. Belali, et al.
Pathology - Research and Practice (2024) Vol. 255, pp. 155180-155180
Closed Access | Times Cited: 8
Unraveling the complexities of colorectal cancer and its promising therapies – An updated review
Sayan Saha, Shreya Ghosh, Suman Ghosh, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113325-113325
Closed Access | Times Cited: 7
Scutebarbatine A induces ROS-mediated DNA damage and apoptosis in breast cancer cells by modulating MAPK and EGFR/Akt signaling pathway
Xiao-shan Hao, Panpan Feng, Yunyun Zhang, et al.
Chemico-Biological Interactions (2023) Vol. 378, pp. 110487-110487
Closed Access | Times Cited: 15
Enhanced in vitro and in vivo anticancer activity through the development of Sunitinib-Loaded nanoniosomes with controlled release and improved uptake
Shiva Dehghan, Amirhossein Naghipour, Fatemeh Zomorodi Anbaji, et al.
International Journal of Pharmaceutics (2023) Vol. 640, pp. 122977-122977
Open Access | Times Cited: 15
MOLECULAR DOCKING AND INVESTIGATION OF BOSWELLIA SERRATA PHYTOCOMPOUNDS AS CANCER THERAPEUTICS TO TARGET GROWTH FACTOR RECEPTORS: AN IN SILICO APPROACH
B. R. JAYASURYA, J. S. SWATHY, Susha Dinesh, et al.
International Journal of Applied Pharmaceutics (2023), pp. 173-183
Open Access | Times Cited: 12
In Vitro Evaluation of Genetically Unmodified Ligand-Armed Allogeneic Natural Killer Cells to Treat EGFR-Positive Glioblastoma
Hortense Courot, Émilie Rigal, N. Adib, et al.
Cells (2025) Vol. 14, Iss. 4, pp. 254-254
Open Access
Design, Synthesis, and Computational Studies of Novel Pyrazoline-Based Dual EGFR/HER2 Inhibitors with Apoptotic Antiproliferative Activity
Lamya H. Al-Wahaibi, Hani M. Hafez, Fadwa H. Edrees, et al.
Journal of Molecular Structure (2025), pp. 142364-142364
Closed Access
Targeted protein degradation with small molecules for cancer immunotherapy
Zichao Yang, Jianwei Xu, Xixiang Yang, et al.
Asian Journal of Pharmaceutical Sciences (2025), pp. 101058-101058
Open Access
Harnessing chitosan-adorned liposomes for enhanced drug delivery in cancer
Mohammad Arshad Javed Shaikh, Obaid Afzal, Waleed Hassan Almalki, et al.
Journal of Drug Delivery Science and Technology (2023) Vol. 85, pp. 104619-104619
Closed Access | Times Cited: 10
Design, synthesis, and antiproliferative screening of new quinoline derivatives bearing a cis-vinyl triamide motif as apoptosis activators and EGFR-TK inhibitors
Hany M. Abd El‐Lateef, Ahmed Gaafar Ahmed Gaafar, Arwa Sultan Alqahtani, et al.
RSC Advances (2024) Vol. 14, Iss. 34, pp. 24781-24790
Open Access | Times Cited: 3
The paradox of autophagy in cancer: NEAT1's role in tumorigenesis and therapeutic resistance
Salem Salman Almujri, Waleed Hassan Almalki
Pathology - Research and Practice (2024) Vol. 262, pp. 155523-155523
Closed Access | Times Cited: 3
A nanotechnology driven effectual localized lung cancer targeting approaches using tyrosine kinases inhibitors: Recent progress, preclinical assessment, challenges, and future perspectives
Ankaj Kumar, Klaudi K. Vaiphei, Arvind Gulbake
International Journal of Pharmaceutics (2024), pp. 124745-124745
Closed Access | Times Cited: 3
Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege
David Rutkowski, Rachel Scholey, John Davies, et al.
British Journal of Dermatology (2024)
Closed Access | Times Cited: 2
Synthesis and biological research of new imidazolone-sulphonamide-pyrimidine hybrids as potential EGFR-TK inhibitors and apoptosis-inducing agents
Dalal Nasser Binjawhar, Hanadi A. Katouah, Najla A. Alshaye, et al.
RSC Advances (2024) Vol. 14, Iss. 28, pp. 20120-20129
Open Access | Times Cited: 2
Dysregulated Signaling Pathways in Canine Mammary Tumor and Human Triple Negative Breast Cancer: Advances and Potential Therapeutic Targets
Chen Mei, Ying Liu, Zhenyi Liu, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 145-145
Open Access | Times Cited: 2
Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources
Samira Tabaei, Mohammad Reza Haghshenas, Thomas J. Webster, et al.
Analytical Biochemistry (2023) Vol. 666, pp. 115074-115074
Closed Access | Times Cited: 6
Discovery of New thieno[2,3- d ]pyrimidines as EGFR Tyrosine Kinase Inhibitors for Cancer Treatment
Eman A. Sobh, Mohammed A. Dahab, Eslam B. Elkaeed, et al.
Future Medicinal Chemistry (2023) Vol. 15, Iss. 13, pp. 1167-1184
Open Access | Times Cited: 6
Transcriptome analysis reveals differences in cell cycle, growth and migration related genes that distinguish fibroblasts derived from pre-invasive and invasive breast cancer
Wei Bin Fang, Marcela Medrano, Paige Cote, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma
Hanwen Lu, Bingchang Zhang, Yuanyuan Xie, et al.
Investigational New Drugs (2023) Vol. 41, Iss. 4, pp. 564-578
Closed Access | Times Cited: 4
Apoptosis-driven synergistic anti-cancer efficacy of ethyl acetate extract of Memecylon sisparense Gamble leaves and doxorubicin in in-vitro and in-vivo models of triple-negative breast cancer
Uppu Jaya Lakshmi, Veerabhadra Swamy, Syamprasad NP, et al.
Pathology - Research and Practice (2023) Vol. 253, pp. 155032-155032
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top